Brandywine Realty trust chooses the PABC team to develop and run its new Philadelphia incubator! << click here >>

Est. by the Hepatitis B Foundation
215-589-6300

Company Spotlight

News about PABC Member Companies
4/14/21
OrthoGenRx Announces Annual Company Highlights, Exceeding Revenue Targets

OrthogenRx, Inc., a medical device company focused on the development and commercialization of treatments focused on the development and commercialization of treatments for knee pain caused by osteoarthritis (OA), recently announced company highlights for 2020 which have exceeded revenue targets.  Among many accomplishments, OrthogenRx is proud to have launched new pricing options to facilitate access to affordable healthcare products, needed more than ever during the health and financial crisis of 2020. Please read more here.

3/03/21
FlowMetric: Neumann University Tests Resident Students for Virus

 All of Neumann’s more than 500 students who moved into residence facilities for the spring semester were asked to present evidence of a negative COVID-19 test, taken within 72 hours of their return to campus in Aston, or take a self-administered test upon arrival. The rapid testing on site was possible because of a mobile testing lab from FlowMetric Life Sciences in Doylestown. Read more here.

2/23/21
Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPA

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, today announced that China's National Medical Products Administration (NMPA) has granted priority review to the New Drug Application. Please read more here.

1/04/21
IO Biosciences Awarded U.S. Patent for GEMSTM Technology, Promising Breakthrough for Those Engineering Antibody Therapies and Therapeutic Gene-modified Immune Cells

Patented GEMS™ technology converts stable cell lines and therapeutic cells into a plug-and-play development system for the expression of single or multiple therapeutic genes, allowing for rapid portfolio development for antibody and gene-modified cell therapies, reducing time between therapeutic discovery and availability to patients. Please read more here.

12/25/20
Evrys Bio: What are the features of the new Covid-19/SARS-CoV-2 strain (named lineage B.1.1.7)?

Recently a distinct phylogenetic cluster (named lineage B.1.1.7) was detected within the COG-UK surveillance dataset. This cluster has been growing rapidly over the past 4 weeks and since been observed in other UK locations, indicating further spread. Please read more here.

12/23/20
Neuropathix Acquires Neuroprotective and Anticonvulsant Intellectual Property Estate

Neuropathix Inc.  has announced it acquired neuroprotective and anticonvulsant small-molecule drug technology from Advanced Neural Dynamics Inc. and Fox Chase Chemical Diversity Center Inc. on Dec. 18. Neuropathix, Advanced Neural Dynamics and Fox Chase Chemical Diversity Center look forward to further characterizing and developing a novel class of anticonvulsant drugs designed to treated refractory epilepsy and neuropathic pain. All three companies are located in the Pennsylvania Biotechnology Center in Doylestown, Pa. Please read more here.

12/16/20
FlowMetric Life Sciences, Inc. Receives Accreditation from the College of American Pathologists (CAP) for its Clinical Laboratory

CAP accreditation is awarded only to laboratories that meet stringent requirements and demonstrate consistency in the high performance and accuracy of clinical testing. Please read more here.

12/13/20
Bucks County pharmaceutical firm sold to California company in multimillion-dollar deal

QrumPharma, a Bucks County biopharmaceutical company developing inhalation treatments for pulmonary infections, was acquired last week by a publicly traded drug developer for $12.8 million. Please read more here.

12/11/20
Putting Patients First: How to Do Your Part… A Small Company’s Perspective

2020 has brought the world to a standstill as we all feel the impact of COVID-19 both on a health and economic level. As the pandemic unfolds, we’ll determine how to react, pivot, and innovate. Read more here. 

12/10/20
Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses (including COVID-19). Read more here.

12/08/20
Single Use Surgical chosen to package and sterilise 1.92 million items of PPE to protect NHS staff against COVID-19

Single Use Surgical*, part of Eakin Healthcare Group, have signed a contract to package and sterilise 1.92 million surgical isolation gowns – a move that will create 45 new jobs and protect frontline NHS staff against COVID-19. Please read more here.

12/04/20
FlowMetric Launches Breakthrough SARS-CoV-2 Serology Assay Superior to Gold Standard

Accurate and sensitive testing to determine the presence of COVID-19 antibodies is essential for the development of safe and effective vaccines and therapeutics targeting the SARS-CoV-2 virus. Until now, the ELISA platform has been the gold standard for antibody testing, despite its limitations. In response to this immediate need, FlowMetric has launched a powerful advancement in SARS-CoV-2 (COVID-19) serology testing with a flow cytometry-based multiplexed serology assay. Please read more here.

12/03/20
Antengene Submits NDAs for XPOVIO® (Selinexor) in Multiple APAC Markets for rrMM and rrDLBCL

Antengene Corporation Limited announced it has submitted new drug applications (“NDA(s)”) for XPOVIO® (selinexor, ATG-010) to the Health Sciences Authority of Singapore and to the Australian Therapeutic Goods Administration for three indications. There is more here.

10/28/20
Colliers LabNotes / Oren Gilad of Atrin Pharmaceuticals

Atrin Pharmaceuticals is one of the many small but powerful companies that are members of, and operating in,  the Pennsylvania Biotechnology Center. Atrin's president and CEO,  Oren Gilad, Ph.D., was interviewed recently by Joe Fetterman of Colliers Philadelphia. To watch the video, click here.

10/06/20
Kannalife, Inc. Adds to Its Global IP Estate Receiving Patent Grant from Canada for Its Novel Anti-Inflammatory Compounds

Kannalife Inc., a biopharmaceutical and medchem company specializing in the research and development of potent novel monotherapeutics, announced today that the company has been issued Canadian Patent CA2936506A1 specific to its patent known as WO2015/106108A2 titled, “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy” (the “PCT Patent”). Read more here.

10/07/20 
Evrys Bio scientist presents at conference on therapeutics for COVID-19

Dr. Liudi Tang of Evrys Bio presented at the Special isirv-AVG Virtual Conference on ‘Therapeutics for COVID-19’ on Oct. 7. He presented the most recent data for one of Evrys Bio’s drug leads, which has been demonstrated to have a broad spectrum of activities against a variety of viruses involved in human disease. The slides that summarize his presentation are posted here.

9/29/20
FlowMetric Life Sciences and Penn State Announce a Collaboration Study on University and Community COVID-19 Antibody Testing

FlowMetric Life Sciences Inc., a global leader in immunology testing services, and the Huck Institutes of the Life Sciences at Penn State University announce the creation of a long-term collaboration study assessing the impact on the Centre County community's potential exposure to COVID-19 by Penn State University students returning to campus. Together with Penn State's Center for Clinical Research, the Huck Institutes will collect thousands of blood samples from Penn State students and members of the Centre County community at the beginning and end of each academic semester for four academic semesters. The samples will be sent to FlowMetric, a GLP-compliant, CLIA-certified, high complexity clinical laboratory located in Doylestown, Pa., for analysis. Read more here.

9/15/20

Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic HBV Subjects Demonstrating Significant, Continuous Reductions in HBsAg

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses (including COVID-19), today reports continued positive data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its proprietary GalNAc delivered RNAi compound. These new data demonstrate that in chronic HBV subjects, a single subcutaneous injection of 90 mg of AB-729 resulted in a mean HBsAg reduction of 1.23 log10 IU/mL at week 12. William Collier, President and Chief Executive Officer of Arbutus, stated, “The 90 mg single-dose 12-week data coupled with our previously disclosed 60 mg single-dose 12-week data mean that we now have two doses which have demonstrated meaningful reductions in HBsAg with a favorable safety and tolerability profile..." Please read more here.

9/14/20

Antengene Announces First Patient Dosed with ATG-010 (selinexor) for Relapsed or Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma

Antengene Corporation, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapies in oncology and hematology, announced today that it has dosed the first patient in a phase Ib clinical trial in China with ATG-010 (selinexor),an oral selective inhibitor of nuclear export (SINE) compound,for the treatment of relapsed or refractory Peripheral T-cell Lymphoma (PTCL) and NK/T-cell Lymphoma (NKTL) (TOUCH trial). This trial aims to evaluate ATG-010 (selinexor) combined with ICE regimen or GEMOX regimen and sequential ATG-010 (selinexor) monotherapy maintenance to evaluate the safety, tolerability and primary efficacy in patients with R/R PTCL and NKTL who have received at least one prior multi-agent therapy. Please read more here.

7/17/20

 The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Grant Entitled "Soft LXR Agonists for Idiopathic Pulmonary Fibrosis"

FCCDC is pleased to announce it has been awarded a Phase I STTR research grant from the NIH with Prof. Ross Summer of Thomas Jefferson University as Principal Investigator, entitled "Soft LXR Agonists for Idiopathic Pulmonary Fibrosis." Read more here.